<DOC>
	<DOCNO>NCT00444678</DOCNO>
	<brief_summary>This trial examine addition Cetuximab combination Oxaliplatin Capecitabine treatment patient previously untreated metastatic colorectal cancer .</brief_summary>
	<brief_title>Cetuximab , Capecitabine Oxaliplatin Patients With Epidermal Growth Factor Receptor ( EGFr ) Expressing Metastatic Colorectal Cancer</brief_title>
	<detailed_description>The current treatment option metastatic colon cancer need improvement . The three-drug combination oxaliplatin 5-FU/LV second-line treatment metastatic colorectal cancer show significant increase response rate compare 5-FU/LV alone . Oxaliplatin recently FDA-approved indication standard first-line agent combination fluoropyrimidine . Cetuximab , chimeric monoclonal antibody growth factor receptor , show activity without irinotecan subject colorectal cancer refractory irinotecan alone . Cetuximab also show safe effective administer infusional 5-FU/folinic acid plus irinotecan . These result suggest addition cetuximab fluoropyrimidine/oxaliplatin-based regimen 1st line setting explore . The use oral fluoropyrimidine , capecitabine , replace infusional 5FU widely use improve convenience possible safety . We choose modified biweekly CapeOx regimen due improve tolerance response rate fix dose capecitabine give widespread practice ease use .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Subjects must sign approve informed consent . Histologically confirm diagnosis advance adenocarcinoma colon rectum , KRAS wild type mutational analysis . No prior chemotherapy metastatic disease ( chemotherapy naive ) . Prior adjuvant therapy 5FU/LV IFL permit complete least six month prior enter study . Measurable disease RECIST criterion define Section 3.3.1 . Subjects tumor tissue available IHC test EGFR expression . ECOG Performance Status 01 . Recovery full previous surgical procedure . Expected survival great 12 week . Subjects least 18 year age . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study 4 week study manner risk pregnancy minimize . WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 72 hour prior start study medication . Adequate hematologic function define absolute neutrophil count ( ANC ) &gt; 1,500/mm3 , platelet count &gt; 100,000/mm3 . Adequate hepatic function define total bilirubin level great 2.0 time upper limit normal ( ULN ) AST ALT level noo great 2.5 time ULN ( AST ALT level great 5 time ULN presence liver metastasis ) . Adequate renal function define serum creatinine level great 1.5 time ULN . WOCBP unwilling unable use acceptable method avoid pregnancy entire study period 4 week study . Women pregnant breastfeeding . Women positive pregnancy test enrollment prior study drug administration . Sexually active fertile men use effective birth control partner woman childbearing potential . Subjects &gt; Grade 1 neuropathy . Any active uncontrolled infection . History myocardial infarction within previous six month current clinical evidence congestive heart failure . History cancer ( except nonmelanoma skin cancer carcinoma situ cervix ) unless complete remission therapy cancer least 5 year . Central nervous system metastasis . Pregnant lactating woman . Men woman reproductive potential must agree use effective contraceptive method . Medical psychiatric disorder would interfere informed consent make poor risk participation trial . Prior allergic reaction chimerized murine monoclonal antibody therapy document presence human antimouse antibody ( HAMA ) . Subjects receive prior investigational agent within 30 day . Prior therapy oxaliplatin , cetuximab , prior therapy target EGF pathway . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious disease ) illness must enrol study . Mutation KRAS gene</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Previously untreated metastatic colorectal cancer</keyword>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>combine therapy</keyword>
	<keyword>biologics therapy</keyword>
	<keyword>antibody</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>EGFR</keyword>
</DOC>